Kolexia
Altwegg Romain Gastro-entérologie
Altwegg Romain
Gastro-entérologie
Hôpital Saint-Éloi
Montpellier, France
180 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Maladies inflammatoires intestinales Maladie de Crohn Rectocolite hémorragique Colite Nécrose Ulcère Abcès Complications postopératoires Nausée

Collaborateurs

Voir plus
Laharie David
Laharie David
Hôpital Haut-lévêque, Pessac, France
Nancey Stephane
Nancey Stephane
Hôpital Lyon Sud, Pierre-Bénite, France
Peyrin-Biroulet Laurent
Peyrin-Biroulet Laurent
Hôpital Brabois, Vandoeuvre-lès-Nancy, France
Vuitton Lucine
Vuitton Lucine
Hôpital Jean-Minjoz, Besançon, France

Industries

Voir plus
Janssen
70 collaboration(s)
Dernière en 2023
Abbvie
50 collaboration(s)
Dernière en 2023
Takeda Pharmaceutical
42 collaboration(s)
Dernière en 2023
Amgen
14 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
LUCENT-URGE: A Multicenter, Phase 3b, Open-Label, Single-Arm Study to Investigate Bowel Urgency and Its Relationship With Other Outcome Measures in Adults With Moderately to Severely Active Ulcerative Colitis Treated With Mirikizumab
Essai Clinique (Lilly)   07 mars 2024
A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease
Essai Clinique (Celgene)   06 mars 2024
Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease: Induction Study #1 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
Essai Clinique (Celgene)   26 février 2024
VERDICT: In actiVE Ulcerative Colitis, a RanDomIzed Controlled Trial for Determination of the Optimal Treatment Target
Essai Clinique (Takeda Pharmaceutical)   20 février 2024
Infliximab is an effective option in patients with ulcerative colitis previously exposed to full subcutaneous anti-TNF agent: Results from a real-world multicenter study.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver   27 janvier 2024
USTAP: USTekinumab in Fistulising Perianal Crohn's Disease (CD): The USTAP CD Study
Essai Clinique (Janssen)   18 janvier 2024
TRENCH 1: TRansmural hEaliNg Definition in CroHn's Disease - The TRENCH1 Study
Essai Clinique (Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives)   15 janvier 2024
ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Study to Evaluate the Efficacy and Safety of ABX464 Once Daily for Induction Treatment in Subjects With Moderately to Severely Active Ulcerative Colitis
Essai Clinique (Abivax S.A.)   15 décembre 2023
ABTECT - Maintenance: A Randomized, Double-blind, Multicenter Phase III Study to Evaluate the Long-term Efficacy and Safety of ABX464 25 mg or 50 mg Once Daily as a Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis
Essai Clinique (Abivax S.A.)   15 décembre 2023
Histological healing induced by tofacitinib in ulcerative colitis: A multicentre study.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver   07 décembre 2023